- Home
- NTRB vs QNCX Comparison
NTRB vs QNCX Comparison
Compare NTRB & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- QNCX
- Stock Information
- Founded
- NTRB 2016
- QNCX 2012
- Country
- NTRB United States
- QNCX United States
- Employees
- NTRB N/A
- QNCX N/A
- Industry
- NTRB Industrial Specialties
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTRB Health Care
- QNCX Health Care
- Exchange
- NTRB Nasdaq
- QNCX Nasdaq
- Market Cap
- NTRB 77.9M
- QNCX 92.3M
- IPO Year
- NTRB N/A
- QNCX 2019
- Fundamental
- Price
- NTRB $4.37
- QNCX $1.95
- Analyst Decision
- NTRB
- QNCX Strong Buy
- Analyst Count
- NTRB 0
- QNCX 3
- Target Price
- NTRB N/A
- QNCX $9.67
- AVG Volume (30 Days)
- NTRB 27.6K
- QNCX 286.7K
- Earning Date
- NTRB 12-04-2024
- QNCX 11-13-2024
- Dividend Yield
- NTRB N/A
- QNCX N/A
- EPS Growth
- NTRB N/A
- QNCX N/A
- EPS
- NTRB N/A
- QNCX N/A
- Revenue
- NTRB $2,021,771.00
- QNCX N/A
- Revenue This Year
- NTRB N/A
- QNCX N/A
- Revenue Next Year
- NTRB N/A
- QNCX N/A
- P/E Ratio
- NTRB N/A
- QNCX N/A
- Revenue Growth
- NTRB N/A
- QNCX N/A
- 52 Week Low
- NTRB $2.22
- QNCX $0.51
- 52 Week High
- NTRB $9.60
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- NTRB 47.75
- QNCX 52.02
- Support Level
- NTRB $3.87
- QNCX $1.80
- Resistance Level
- NTRB $4.86
- QNCX $2.09
- Average True Range (ATR)
- NTRB 0.48
- QNCX 0.21
- MACD
- NTRB 0.08
- QNCX -0.05
- Stochastic Oscillator
- NTRB 65.05
- QNCX 27.01
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.